MIMOSA: Guiding De Novo Antibody Design with Natural Interaction Fingerprints
De novo antibody design promises to transform therapeutic antibody and nanobody discovery. Yet, success remains inconsistent across targets, with generative models often yielding no experimentally validated binders. Here we introduce MIMOSA (MIMic-Oriented Structural Antibody generation), a model-agnostic, inference-time framework that constrains diffusion-based antibody design pipelines to…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
